Javascript must be enabled to continue!
18F-FDG-PET/CT in unexplained elevated inflammatory markers
View through CrossRef
SummaryThe diagnostic strategy in patients with fever or inflammation of unknown origin remains a major clinical challenge. The aim of this study was to evaluate the role of 18F-FDG-PET/CT in patients with unexplained elevated C-reactive protein with or without fever. Contribution of 18F-FDG-PET/CT to the final diagnosis was evaluated. In addition we determined whether a differentiation between patients with or without fever is clinically reasonable. Patients, methods: We retrospectively analysed 72 consecutive patients with unexplained elevated C-reactive protein levels (above 8mg/l) that underwent 18F-FDG-PET/ CT in our facility between 10/2009 and 11/2012. 18F-FDG-PET/CT was considered a so-called diagnostic scan when results decisively led to a final diagnosis and adequate therapy with a response of symptoms was initiated due to the PET/CT result. Results: In 60/72 patients (83%) a final diagnosis was established. Diagnoses included infections (58%), non-infectious inflammatory diseases (29%) and malignancies (8%). 18F-FDG-PET/CT was true positive in 47 cases (65%) and the diagnostic scan in 29 patients (40%). Sensitivity of 18F-FDG-PET/CT was 81% and specificity was 86%. Diagnostics, final diagnoses, 18F-FDG-PET/CT results, SUVmax, C-reactive protein levels and the diagnostic scan did not differ significantly between patients with fever and patients without fever. Conclusion: 18F-FDG-PET/CT is a useful method in the diagnostic workup of patients with inflammation of unknown origin. In our series there was no significant difference between patients with or without fever. Regarding 18F-FDG-PET/CT-imaging inflammation of unknown origin and unexplained fever can be joined to one entity.
Georg Thieme Verlag KG
Title: 18F-FDG-PET/CT in unexplained elevated inflammatory markers
Description:
SummaryThe diagnostic strategy in patients with fever or inflammation of unknown origin remains a major clinical challenge.
The aim of this study was to evaluate the role of 18F-FDG-PET/CT in patients with unexplained elevated C-reactive protein with or without fever.
Contribution of 18F-FDG-PET/CT to the final diagnosis was evaluated.
In addition we determined whether a differentiation between patients with or without fever is clinically reasonable.
Patients, methods: We retrospectively analysed 72 consecutive patients with unexplained elevated C-reactive protein levels (above 8mg/l) that underwent 18F-FDG-PET/ CT in our facility between 10/2009 and 11/2012.
18F-FDG-PET/CT was considered a so-called diagnostic scan when results decisively led to a final diagnosis and adequate therapy with a response of symptoms was initiated due to the PET/CT result.
Results: In 60/72 patients (83%) a final diagnosis was established.
Diagnoses included infections (58%), non-infectious inflammatory diseases (29%) and malignancies (8%).
18F-FDG-PET/CT was true positive in 47 cases (65%) and the diagnostic scan in 29 patients (40%).
Sensitivity of 18F-FDG-PET/CT was 81% and specificity was 86%.
Diagnostics, final diagnoses, 18F-FDG-PET/CT results, SUVmax, C-reactive protein levels and the diagnostic scan did not differ significantly between patients with fever and patients without fever.
Conclusion: 18F-FDG-PET/CT is a useful method in the diagnostic workup of patients with inflammation of unknown origin.
In our series there was no significant difference between patients with or without fever.
Regarding 18F-FDG-PET/CT-imaging inflammation of unknown origin and unexplained fever can be joined to one entity.
Related Results
Baseline Staging Evaluation in Lymphoma: The Role of FDG PET, CT, and Bone Marrow Biopsy
Baseline Staging Evaluation in Lymphoma: The Role of FDG PET, CT, and Bone Marrow Biopsy
Abstract
Abstract 2640
BACKGROUND:
The revised response criteria for malignant lymphoma (Cheson et al JCO 25:579 ...
Clinical and 18F-FDG PET/CT Imaging Characteristics of Post-radiotherapy Sacral Insufficiency Fractures in Cervical Cancer Patients
Clinical and 18F-FDG PET/CT Imaging Characteristics of Post-radiotherapy Sacral Insufficiency Fractures in Cervical Cancer Patients
Introduction:
Sacral Insufficiency Fractures (SIFs) are a common yet frequently misdiagnosed late complication following pelvic radiotherapy for cervical
cancer...
Semi-Quantitative Evaluation of Pre-Transplant FDG-PET in Relapsed and Refractory Hodgkin Lymphoma
Semi-Quantitative Evaluation of Pre-Transplant FDG-PET in Relapsed and Refractory Hodgkin Lymphoma
Abstract
Abstract 2015
Introduction:
We previously reported the prognostic impact of pre-transplant functional im...
Diagnostic value of 18F-FDG PET/MRI for staging in patients with ovarian cancer
Diagnostic value of 18F-FDG PET/MRI for staging in patients with ovarian cancer
Abstract
Purpose: To evaluate the diagnostic potential of PET/MRI with 18F-fluorodeoxyglucose (18F-FDG) in ovarian cancer.Materials and Methods: Participants comprised 103 ...
Diagnostic value of [18F]FDG PET/MRI for staging in patients with ovarian cancer
Diagnostic value of [18F]FDG PET/MRI for staging in patients with ovarian cancer
Abstract
Purpose: To evaluate the diagnostic potential of PET/MRI with 2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG) in ovarian cancer.Materials and Methods: Participants comp...
Diagnostic Value of 18F-FDG PET/MRI For Staging in Patients With Ovarian Cancer
Diagnostic Value of 18F-FDG PET/MRI For Staging in Patients With Ovarian Cancer
Abstract
Purpose
To evaluate the diagnostic potential of PET/MRI with 18F-fluorodeoxyglucose (18F-FDG) in ovarian cancer.
Materials and Methods
Participants comprised 103...
[18F] Fludarabine pour l'imagerie TEP des lymphomes
[18F] Fludarabine pour l'imagerie TEP des lymphomes
Bien que l’utilité de la TEP au [18F]FDG soit confirmée pour le diagnostic et le suivi thérapeutique chez les patients atteints de lymphome, la spécificité de la captation du [18F]...
Bridging bones
Bridging bones
Chapter 2 presents the evaluation of the feasibility of utilizing whole-body [18F]Fluoride PET/CT for visualizing molecular new bone formation in clinically active PsA patients. Th...

